title: Effects of early inhaled beclomethasone therapy on tracheal aspirate inflammatory mediators IL-8 and IL-1ra in ventilated preterm infants at risk for bronchopulmonary dysplasia.
abstract: We tested the hypothesis that inhaled beclomethasone therapy for prevention of bronchopulmonary dysplasia (BPD) reduces pulmonary inflammation. As part of a randomized, placebo-controlled trial, interleukin-8 (IL-8) and interleukin-1 receptor antagonist (IL-1ra) concentrations in tracheal aspirates were measured as markers of pulmonary inflammation. On study days 1 (baseline), 8, 15, and day 28 of age, samples were obtained from enrolled infants (birth weights <1,251 g, gestational age <33 week, 3 to 14 days of age) who remained ventilated and had not received systemic glucocorticoid therapy. Cytokine levels (pg/microg of free secretory component of immunoglobulin A) were compared between groups. We determined whether baseline cytokine levels modified treatment effect regarding subsequent need for systemic glucocorticoid therapy or occurrence of BPD (age 28 days). Tracheal aspirates were obtained from 161 infants (77 receiving beclomethasone, 84 receiving placebo). Median IL-8 levels were lower in beclomethasone versus placebo infants on study days 8 (82.9 vs. 209.2, P < 0.01) and 15 (37.4 vs. 77.4, P < 0.03) after controlling for antenatal glucocorticoid therapy and maternal race. Median IL-1ra levels were lower in beclomethasone versus placebo infants only on study day 8 (86.5 vs. 153.3, P < 0.01). Fewer beclomethasone infants with baseline IL-8 levels in the interquartile range required systemic glucocorticoid therapy (beclomethasone 30.6% vs. placebo 65.8%, P < 0.01) or developed BPD (beclomethasone 42.4% vs. placebo 69.4%, P < 0.03). We conclude that early-inhaled beclomethasone therapy was associated with a reduction in pulmonary inflammation after 1 week of therapy. Beclomethasone-treated infants with moderately elevated baseline IL-8 levels received less subsequent systemic glucocorticoid therapy and had a lower incidence of BPD than nontreated infants.
authors.affiliation: Department of Pediatrics, Division of Newborn Medicine, The Floating Hospital for Children at New England Medical Center, Tufts University School of Medicine, Boston, Massachusetts, USA.
authors.forename: G K
authors.initials: GK
authors.lastname: Gupta
authors.forename: C H
authors.initials: CH
authors.lastname: Cole
authors.forename: S
authors.initials: S
authors.lastname: Abbasi
authors.forename: S
authors.initials: S
authors.lastname: Demissie
authors.forename: C
authors.initials: C
authors.lastname: Njinimbam
authors.forename: H C
authors.initials: HC
authors.lastname: Nielsen
authors.forename: T
authors.initials: T
authors.lastname: Colton
authors.forename: I D
authors.initials: ID
authors.lastname: Frantz
mesh_terms: D000280:Administration, Inhalation; D001507:Beclomethasone / Q000627:therapeutic use*; D001826:Body Fluids / Q000737:chemistry*; D001997:Bronchopulmonary Dysplasia / Q000517:prevention & control*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007235:Infant, Premature, Diseases / Q000188:drug therapy*; D018836:Inflammation Mediators / Q000032:analysis*; D016209:Interleukin-8 / Q000032:analysis*; D008297:Male; D017472:Receptors, Interleukin-1 / Q000032:analysis*; D012121:Respiration, Artificial; D014132:Trachea
chemical_list: D005938:Glucocorticoids; D018836:Inflammation Mediators; D016209:Interleukin-8; D017472:Receptors, Interleukin-1; D001507:Beclomethasone